Skip to main content

Table 2 Comparison of patients characteristics according to the sickle cell haplotypes

From: High fetal hemoglobin level is associated with increased risk of cerebral vasculopathy in children with sickle cell disease in Mayotte

 Homozygous BantuHeterozygous BantuHomozygous BeninHeterozygous Benin
Bantu/Bantu (n = 95)PBantu/− (n = 46)PBenin/Benin (n = 4)PBenin/− (n = 35)p
Mean (±SD) or n (%)Mean (±SD) or n (%)Mean (±SD) or n (%)Mean (±SD) or n (%)
Age (years)         7,98 (±0,82)11,23 (±0,55)0,002
Hématocrit (%)24,18 (±0,38)26,26(±0,51)0,001      26,26 (±0,6)24,43 (±0,36)0,01
MCV (fL)81,27 (±1)67,78 (±1,23)< 0,001      66,72 (±1,42)80,04 (±0,97)< 0,001
MCHC (g/dL)32,75 (±0,13)31,43 (±0,24)< 0,00132,22 (±0,13)33,72 (±0,74)0,02334,25 (±1,04)32,23 (±0,13)0,011   
HbF (%)   13,11 (±0,7)6,08 (±2,3)0,0444,01 (±2,7)13,07 (±0,7)0,03412 (±0,75)15,1 (±1,52)0,048
HbS (%)85,9 (±1,1)79,67 (±1,36)0,001      78,68 (±1,62)85,48 (±0,98)0,001
TCD        0,041   
Normal      1 (33,3)101 (83,4)    
Limit      010 (8,3)    
Pathological      2 (66,7)10 (8,3)    
Duration of follow-up (months)   87,57 (±5,03)143,7 (±30,43)0,032153 (±37,4)87,7 (±5)0,025   
Newborn screening         29 (74,3)8 (7,3)0,001
Treatment Iron chelator      2 (50%)9 (6,3)0,028   
Hospitalization/year  0,012        0,002
No9 (9,6)13 (25,5)       12 (30,7)10 (9,5) 
1 à 275 (79,8)37 (72,5)       27 (69,3)85 (80) 
≥310 (10,6)1 (2)       011 (10,5) 
RBC transfusion  0,046         
Never18 (18,9)19 (37,3)          
Occasionnally63 (66,4)28 (54,9)          
chronic transfusion14 (14,7)4 (7,8)